Ukraine war, China's COVID lockdown and more could weigh on J&J's early-year performance—and it may not be alone: analysts

As the world contends with an interminable pandemic and a shocking escalation of tensions in Europe, the pharmaceutical industry is not immune.

World events have prompted Cantor Fitzgerald analysts to dial back their first-quarter sales expectations for Johnson & Johnson—and it’s possible other big pharmas could be affected, too.

Weighing the ongoing stresses of the war in Ukraine, COVID-19 lockdowns in China and the strengthening of the U.S. dollar, the analysts have lowered their first-quarter sales forecast for the New Jersey drug major from $23 billion to $22.6 billion.